Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Martin Huth Ruwald, MD,* Morten Lock Hansen, MD, PhD,* Morten Lamberts, MD,* Carolina Malta Hansen, MD,* Michael Vinther, MD, PhD,* Lars Køber, MD, DMSc,† Christian Torp-Pedersen, MD, DMSc,* Jim Hansen, MD, DMSc,* Gunnar Hilmar Gislason, MD, PhD*
Hellerup and Copenhagen, Denmark

JACC JOURNAL CME

This article has been selected as the month’s JACC Journal CME activity.

Accreditation and Designation Statement
The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation and Receipt of CME Certificate
To obtain credit for JACC CME, you must:
1. Be an ACC member or JACC subscriber.
2. Carefully read the CME-designated article available online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME Objective for This Article: At the conclusion of this activity, the learner should be able to examine the risk of major adverse events and death in a nationwide cohort of patients without previous comorbidity admitted for syncope.

CME Editor Disclosure: JACC CME Editor Ajit Raisinghani, MD, FACC, reports that he has no financial relationships or interests to disclose.

Author Disclosures: Dr. Torp-Pedersen is a consultant to Sanofi-Aventis, Merck, and Cardiome, and receives consulting fees from all three companies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Print (article only); online (article and quiz)

CME Term of Approval:
Issue date: January 22, 2013
Expiration date: January 21, 2014

*From the Department of Cardiology, Gentofte Hospital, Hellerup, Denmark; and the †Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Dr. Torp-Pedersen is a consultant to Sanofi-Aventis, Merck, and Cardiome, and receives consulting fees from all three companies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Manuscript received July 20, 2012; accepted August 7, 2012.
Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

Objectives
This study sought to examine the risk of major cardiac adverse events and death in a nationwide cohort of patients without previous comorbidity admitted for syncope.

Background
Syncope is a common clinical event, but knowledge of prognosis is not fully elucidated in healthy individuals.

Methods
Patients without previous comorbidity admitted for syncope in Denmark from 2001 to 2009 were identified in nationwide administrative registries and matched by sex and age with 5 control subjects from the Danish population. The risk of death or recurrent syncope, implantation of pacemaker or implantable cardioverter-defibrillator, and cardiovascular hospitalization were analyzed with multivariable Cox proportional hazard models.

Results
We identified 37,017 patients with a first-time diagnosis of syncope and 185,085 control subjects; their median age was 47 years (interquartile range, 32 to 63 years) and 47% were male. A total of 3,023 (8.2%) and 14,251 (7.1%) deaths occurred in the syncope and the control population, respectively, yielding an event rate of 14.3 per 1,000 person-years (PY) in the syncope population. Multivariable Cox regression analysis demonstrated a significantly increased risk of all-cause mortality (hazard ratio [HR]: 1.06; 95% confidence interval [CI]: 1.02 to 1.10), cardiovascular hospitalization event rate of 26.5 per 1,000 PY (HR: 1.74; 95% CI: 1.68 to 1.80), recurrent syncope event rate of 45.1 per 1,000, stroke event rate of 6.8 per 1,000 PY (HR: 1.35; 95% CI: 1.27 to 1.44), and pacemaker or implantable cardioverter-defibrillator event rate of 4.2 per 1,000 PY (HR: 5.52; 95% CI: 4.67 to 5.73; p < 0.0001).

Conclusions
The first admission for syncope among healthy individuals significantly predicts the risk of all-cause mortality, stroke, cardiovascular hospitalization, device implantation, and recurrent syncope.

Methods
A personal and unique civil registration number (CPR number) is assigned to all residents in Denmark that enables linkage of nationwide administrative registries on the individual level. Information on all dispensed prescriptions from Danish pharmacies since 1995 is registered according to the Anatomical Therapeutic Chemical system in the Danish Register of Medicinal Products (21). We obtained information on hospitalization and comorbidities from the Danish National Patient Register, where information on all hospital admissions in Denmark has been stored since 1978 (22). At discharge, each hospital admission is coded with 1 primary diagnosis and, if appropriate, 1 or more secondary diagnoses according to the International Classification of Diseases (ICD), before 1994, the 8th revision, and from 1994 to date, the 10th revision (ICD-10). Demographic information on date of birth, age, sex, and vital status were obtained from the Danish Civil Register.

Study population. From the Danish National Patient Register, we identified all Danish residents with a first-time admission to hospital or ED visit for syncope when classified as the primary discharge diagnosis (ICD-10 code R55.9) between January 1, 2001, and December 31, 2009. All hospital admissions, ED contacts, and nonacute referrals (i.e., outpatients were included but each unique patient was only recorded once). R55.9 refers to “syncope and collapse.” Patients seen in the ED, given the discharge diagnosis of R55.9, and immediately hospitalized were included if they
retained the diagnosis of R55.9 during the hospital admission and were discharged with that diagnosis. All secondary diagnoses given at the same index hospitalization were recorded. After identification, every syncope patient was matched by age and sex with 5 random control subjects from the Danish population. The control subjects were assigned the same date of syncope as the case with which they were matched (risk set matching). The “greedy macro match” algorithm was used to identify the matched control population (23).

**Comorbidity and pharmacotherapy.** Identification and information on major comorbidities related to syncope up to 5 years before the index date for syncope admission or ED visit were based on hospital discharge diagnosis codes according to a modified Charlson Comorbidity Index (24,25). We obtained information through the Danish National Patient Register based on the primary or secondary diagnosis for the following ICD-10 codes: cerebral vascular disease (I60 through I69), ischemic heart disease (I20 through I25), previous myocardial infarction (I21, I22), cardiac conduction disorders (I44, I45), atrial fibrillation (I48, I49), other cardiac arrhythmias (I46, I47), heart failure (I42, I50), chronic renal failure (N18, I12, I13), acute renal failure (N17, N19, R34), pulmonary edema (J81), shock (R57, A41), chronic obstructive pulmonary disease (J42 through J44), and cancer (C00 through C97). Hypertension was defined as treatment. We identified patients with hypertension from combination treatment with at least 2 of the classes of antihypertensive drugs as defined in the Online Appendix. This definition of hypertension was validated in a previously described, randomly selected cohort (23). We defined diabetes mellitus as a claimed prescription for a glucose-lowering drug (A10) or admission for diabetes with or without complications (E10 through E14).

Information on concomitant drug use up to 6 months before syncope was provided through the Register of Medicinal Product Statistics using the following Anatomical Therapeutic Chemical system codes: statins (C10A), beta-blockers (C07), angiotensin-converting enzyme inhibitors (C09), loop diuretics (C03C), spironolactone (C03D), thiazides (C03A), calcium channel blockers (C08), digoxin (C01A), class I antiarrhythmic drugs (C01BC), class III antiarrhythmic drugs (C01BD and C07AA), class IV antiarrhythmic drugs (C08DA), morphine (N02AA), glucose-lowering medication (A10), clopidogrel (B01AC04), acetylsalicylic acid (B01AA0), vitamin K antagonists (B01AA0), sedative and anxiolytic agents (N05B, N05C), antipsychotic agents (N05A), and bronchodilators (R04).

To define the population of patients with no comorbidity, we therefore excluded all patients who had been hospitalized previously with any of the comorbidities listed in Table 1 and who had claimed prescription of selected pharmacotherapy within 180 days as defined in the Online Appendix.

**Validation population.** We previously validated the discharge diagnosis of R55.9 and found a positive predictive value of 95% and a sensitivity of 61% (27).

**Outcome measures.** Survival status (whether patient is dead or alive) is obtained from the National Person Register. Cause of death is obtained from the National Danish Registry of Causes of Death. The primary outcomes are long-term all-cause mortality and within 1 year. Secondary outcomes are insertion of an implantable cardioverter-defibrillator or pacemaker, admission for stroke, or cardiovascular hospitalization and admission for recurrent syncope. These outcomes are gathered from the Danish Patient Registry according to ICD-10 discharge diagnosis and procedural codes.

**Statistical analyses.** Data are presented as number and percentage or mean and SD. Data not normal distributed are presented as the median and interquartile range. Differences between categorical variables were analyzed with the chi-square test and differences between continuous variables with the Wilcoxon rank sum test or the Kruskal-Wallis test.

Events and outcomes were individually evaluated and then analyzed by Cox regression analysis, competing model analysis, and cumulative incidence calculations. All models were tested for linearity of continuous variables. All analyses were done using SAS statistical software, version 9.2 (SAS Institute Inc., Cary, North Carolina).

**Ethics.** The study was accepted by the Danish Data Protection Agency (ref. 2007-58-0015, int. ref: GEH-2010-001). Ethical approval is not required for registry-based studies in Denmark, and all data are anonymous and encrypted.

**Results**

We identified 88,335 patients with syncope, of whom 37,017 patients had no known previous hospitalization for comorbidities and no concomitant use of selected pharmacotherapy as listed in Table 1. The mean follow-up was 4.5 years. The complete sex- and age-matched control population comprised 185,085 individuals. The control group or background population was likewise a low-risk population with the Wilcoxon rank sum test or the Kruskal-Wallis test.

Events and outcomes were individually evaluated and then analyzed by Cox regression analysis, competing model analysis, and cumulative incidence calculations. All models were tested for linearity of continuous variables. All analyses were done using SAS statistical software, version 9.2 (SAS Institute Inc., Cary, North Carolina).
ratios (HRs) in Table 2. The youngest age group in the syncope population only accounted for 1 death (0.0%), whereas 26 deaths (0.2%) occurred in those between 25 and 44 years of age and 268 deaths (1.7%) occurred in those between 45 and 75 years of age. There were 401 deaths (8.8%) within 1 year in the oldest age group. The event rates of all-cause mortality within the first year were 15.3 per 1,000 person-years (PY) in the syncope population and 16.3 per 1,000 PY in the control group.

Long-term mortality. The overall mortality was 8.2% (3,023 deaths) in the syncope population and 7.7% (14,251 deaths) in the control population, with an HR of 1.06 (95% confidence interval [CI]: 1.02 to 1.10) and a p value of 0.0033. The event rate for all-cause mortality was 14.3 per 1,000 PY for the syncope patients compared with 13.3 per 1,000 PY for the control subjects, and the mortality was increased in the syncope population across all age groups.
younger than 75 years of age. The HR was 1.6 (95% CI: 1.03 to 2.68) in the youngest age group (younger than 25 years of age) (Table 3). The HR in the age group ranging from 25 to 44 years of age was 2.29 (95% CI: 1.87 to 2.80). In the middle-aged population (45 to 74 years of age), the HR was 1.23 (95% CI: 1.15 to 1.31) and 0.98 (95% CI: 0.94 to 1.01) in the elderly. We found no significant difference in long-term cardiovascular mortality between the 2 groups (event rate: 11.1 and 11.2 per 1,000 PY, p = 0.4204). The cumulative incidence plot in Figure 1 shows long-term mortality across age groups, and Figure 2 shows the cumulative incidence plot for the selected age group of 45 to 74 years of age.

The development of cardiovascular comorbidity, stroke, and the risk of device implantation after presentation of first syncopal event in a healthy population. A total of 4,183 patients in the syncope population were hospitalized for cardiovascular reasons. The event rate of cardiovascular hospitalization was found significantly increased in the syncope population, with an event rate of 26.5 per 1,000 PY versus 15.3 per 1,000 PY, respectively (HR: 1.74; 95% CI: 1.68 to 1.80; p < 0.0001). Similarly, we found an increased risk of device implantation with an event rate of 4.2 per 1,000 PY versus 0.8 per 1,000 PY, respectively (HR: 5.52; 95% CI: 4.67 to 5.73; p < 0.0001). The total amount of implanted devices in the syncope population was 698. A total of 1,131 patients experienced a stroke in the syncope population, and the event rate of strokes was 6.8 versus 5.0 in the control population (HR: 1.35; 95% CI: 1.27 to 1.44; p < 0.0001). Data are presented in Figures 3 to 5.

Discussion

This nationwide retrospective cohort study reveals novel insights into the patterns of short- and long-term mortality after an ED visit or admission for syncope in supposedly healthy patients. First, we found a short-term increased risk of death in the age groups between 25 and 74 years; however measured in all age groups, only borderline significance was noted between the 2 groups. Second, we found a significantly increased risk of all-cause long-term mortality across all age groups, and, finally, in our subgroup analysis, we found a higher risk of death in those 44 to 75 years of age, representing a group at especially increased risk. Furthermore, our results showed that syncope as a first symptom significantly predicted several adverse outcomes such as an increased risk of stroke, device implantation, and cardiovascular hospitalization.
Not surprisingly, we found a very high event rate of recurrent syncope that was also confirmed in the multivariable adjusted Cox regression analysis. However, the event rate, in numbers not previously seen, describes very well what is observed by clinicians—that the syncope patient is seen in hospital several times and most likely is submitted to several tests, which have low diagnostic yield. Furthermore, previous studies have shown that recurrent syncope increases the risk of fractures and diminishes quality of life markedly to levels of patients with rheumatoid arthritis and epilepsy (16,17,28).

We defined the syncope population with no comorbidities according to their lack of hospitalizations in the previous 5 years combined with no use of selected prescription drugs. The use of other prescription drugs in the syncope group was low and did not exceed that by the control group on any points. The increased rate of syncope among patients with psychiatric disease was described previously, and antipsychotics in particular are associated with syncope, so we chose to include this as a selected pharmacotherapy to exclude from the study population (29–31). With regard to the other types of drugs, we found significantly lower use than in the control population. This supports that our syncope population can be recognized as a presumably “healthy” group. Generally, the use of prescription drugs in the control population was likewise low, indicating that this

### Table 4

<table>
<thead>
<tr>
<th>Age Group, yrs</th>
<th>Event Rates per 1,000 PY</th>
<th>HR</th>
<th>95% CI</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;25</td>
<td>35.4</td>
<td>312.37</td>
<td>187.49–520.42</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>26–44</td>
<td>38.7</td>
<td>545.70</td>
<td>343.10–867.94</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>45–74</td>
<td>46.9</td>
<td>135.13</td>
<td>111.86–163.23</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>&gt;75</td>
<td>74.7</td>
<td>37.75</td>
<td>31.94–44.63</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>All age groups</td>
<td>45.1</td>
<td>118.27</td>
<td>105.38–132.73</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

PY = patient year; other abbreviations as in Table 2.
is representative of the background population and comparison between the 2 groups is justified. Furthermore, we assessed the secondary discharge diagnoses, and in only one sixth of the syncope patients was there a secondary diagnosis, indicating that, as suspected, syncope was the primary reason for admission and the prominent symptom during the hospitalization. Important secondary diagnoses in terms of mortality and relevancy to syncope relates to heart failure, aortic stenosis, cerebral infarction, and ischemic heart disease. These secondary diagnoses are, in our data, very limited in terms of absolute and relative numbers, and relevant cardiovascular disease discovered during the actual and first hospitalization, represented by secondary discharge diagnoses, is low. The secondary diagnoses are given in Online Table.

Syncope as a predictor of mortality in the young and the elderly. We found a significantly increased risk of death in the 25- to 44-year age group. This is important new information not previously shown in larger studies. We hypothesize that this group of patients may be underdiagnosed in terms of unrecognized cardiovascular disease revealing a worse prognosis.

We found no significant association of increased all-cause mortality or cardiovascular death in the elderly, but this may largely be due to our control population. Therefore, it is reasonable to assume that the true HR ratio of this subgroup of our population would be higher if compared with a control population of no comorbidity.

Mortality due to cardiovascular disease. Soteriades et al. (5) followed 7,814 patients in the general population with syncope for 17 years and found a higher mortality rate for patients with cardiac syncope compared with noncardiac syncope. Suzuki et al. (18) studied 912 patients with syncope for an average of 3 years and found the same result. A retrospective study of 1,516 patients showed, however, no difference in the survival after syncope between causes of syncope (divided into groups of unexplained, cardiovascular, and noncardiovascular) (8). Our study fills a gap in knowledge, and the interpretation of the increased risk in mortality in certain age groups deserves extra attention. It may not be safe to rely on a history of no comorbidity when evaluating a patient with syncope, as some studies suggest.

A study comparing patients with and without syncope matched for cardiovascular disease and other important clinical variables found that cardiac syncope (per se) was not a significant predictor of overall or cardiac 1-year survival (10). Rather, underlying heart disease, particularly heart failure, was found to be the significant survival predictor. Likewise, a study of hospitalized syncope patients (8) found that the risk of death was not associated with a cardiac cause but correlated with age and comorbidity, which also included cardiovascular diseases. In a study of patients with advanced heart failure, poor left ventricular function was associated with a high risk of sudden death, regardless of the cause of syncope (19). Overall, there are discrepancies regarding the mortality of syncope. Our study clearly indicates that syncope as a first symptom in healthy people represents an increased risk of death and may be the first symptom of underlying cardiovascular disease.

This study is important to the clinician when evaluating the prognosis of otherwise healthy individuals who have experienced syncope. More studies, however, are needed and, more importantly, proper risk stratification. Our study particularly fills a gap in the evaluation of the healthy younger and elderly who seem at the same risk as the background population, where, however, more studies are needed to clarify the much higher risk associated with the middle age groups in terms of mortality and development of cardiovascular disease.

Important strengths of the study include the long follow-up period, the large size of our study sample, and the fact that it was based on a nationwide unselected cohort of patients with syncope in a clinical setting. The Danish National Patient Register is the only nationally representative dataset that provides descriptive information about Danish ED visits. By including information from nationwide registries, we minimize the risk of selection bias. This study included patients independent of sex, socioeconomic status, age, ethnicity and participation in insurance or health programs and, importantly, included patients independent of participation in the labor market. Validation of the accuracy of a very similar ICD-9 (780.2) code in the United States was performed by Gabayan et al. (32) (n = 100), demonstrating a positive predictive value of 92% and a negative predictive value of 100%. In a substudy, we validated 750 charts with the diagnosis R559 and found a positive predictive value of 95% and 5,652 randomly selected medical patients and found the sensitivity of syncope to be 61%. This means that at least one third of the patients hospitalized for syncope in the Danish registries are not coded as syncope in the discharge diagnosis, which may create a bias toward a more benign outcome as some cardiovascular syncope cases are coded as specific cardiac causes (i.e., aortic stenosis or ventricular tachycardia).

Study limitations. The main limitation is inherent in the observational nature of the study and the lack of clinical data, particularly, electrocardiographic data. The assumption that the patients were without comorbidity was based on the lack of hospital contact for comorbidities and on the lack of use of selected pharmacotherapy. However, considering the fact that the patients did not take more medications for other conditions than the control group, we must assume that they at least had no more comorbidities than the control group. Our case ascertainment strategy could not identify individuals with syncope who had an alternative discharge diagnosis and did not have syncope coded as the principal ICD-10 discharge diagnosis. Furthermore, it is an inherent weakness that our outcome is based on hospital discharge diagnosis rather than adjudicated events.
Conclusions

First admission for syncope in a population without previous comorbidity significantly predicts the risk of all-cause mortality, stroke, cardiovascular hospitalization, device implantation, and recurrent syncope. The study suggests that syncope in seemingly healthy persons may be a first symptom of a more severe underlying cardiovascular disease.

REFERENCES


Key Words: cardiovascular events ▪ epidemiology ▪ prognosis ▪ syncope.

APPENDIX

For supplemental text and a table, please see the online version of this article.

Go to http://cme.jaccjournals.org to take the CME quiz for this article.